

**Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)**

**Adverse events should also be reported to McNeil Products Limited on 01344 864 042.**

#### Short-form EI

**Non-Drowsy Sudafed Decongestant Nasal Spray/ Sudafed Blocked Nose Spray/ Sudafed Mucus Relief 0.1% Nasal Spray/ Sudafed Sinus-Ease 0.1% Nasal Spray (Xylometazoline Hydrochloride 0.1% w/v)**

#### **Product Information**

**Presentation:** Metered dose bottle containing 0.1% w/v Xylometazoline hydrochloride as an aqueous solution.

#### **Uses:**

Symptomatic relief of nasal congestion associated with colds, influenza, sinusitis, and rhinitis and other upper respiratory tract allergies.

#### **Dosage:**

*Adults and children 12 years and over:* 1 spray into each nostril 2 – 3 times daily up to a maximum of 3 sprays daily. *Children under 12 years:* Not recommended.

#### **Contraindications:**

Hypersensitivity to ingredients, with or within 2 weeks of receiving MAOIs, hypophysectomy or surgery exposing dura mater.

#### **Precautions:**

Coronary artery disease, hypertension, diabetes mellitus, hyperthyroidism. Patients with long QT syndrome. Prolonged treatment may lead to reactive hyperemia of the nasal mucosa. This medicine contains 1.96 mg benzalkonium chloride in each 10 ml, and 2.94 mg benzalkonium chloride in each 15 ml, which is equivalent to 0.196 mg/ml of product. Benzalkonium chloride may cause irritation or swelling inside the nose, especially if used for a long time. Long-term use may cause oedema of the nasal mucosa.

#### **Pregnancy and Lactation:**

Not recommended

#### **Side effects:**

*Not Known:* burning sensation mucosal, nasal discomfort, nasal dryness, nasal pruritus, rhinalgia, sneezing, rebound congestion. *Uncommon:* Epistaxis *Rare:* nausea and headache.

**RRP (ex VAT):** £4.18

**Legal category:** GSL

**PL Holder:** McNeil Products Ltd., 50 - 100 Holmers Farm Way High Wycombe, Buckinghamshire, HP12 4EG, UK

**PL Number:** PL 15513/0074

**Date of prep:** 23 JUN 2021